http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 31 Jul 2026 16:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DBV+Technologies+S.A.+++++For%3A+Jul+29++Filed+by%3A+Mohideen+Pharis/26850899.html si-local-file:///var/storage/secattach/20260731/26850899.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DBV+Technologies+S.A.+++++For%3A+Jul+29++Filed+by%3A+Mohideen+Pharis/26850899.html Fri, 31 Jul 2026 16:15:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DBV+Technologies+S.A.+++++For%3A+Jul+29++Filed+by%3A+Mohideen+Pharis/26850899.html si-local-file:///var/storage/secattach/20260731/26850899.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DBV+Technologies+S.A.+++++For%3A+Jul+29++Filed+by%3A+Mohideen+Pharis/26850899.html Fri, 31 Jul 2026 16:15:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DBV+Technologies+S.A.+++++For%3A+Jul+29++Filed+by%3A+Mohideen+Pharis/26850899.html si-local-file:///var/storage/secattach/20260731/26850899.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DBV+Technologies+S.A.+++++For%3A+Jul+29++Filed+by%3A+Mohideen+Pharis/26850899.html Fri, 31 Jul 2026 16:15:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html si-local-file:///var/storage/secattach/20260416/26325752.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html Thu, 16 Apr 2026 16:52:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html si-local-file:///var/storage/secattach/20260416/26325752.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html Thu, 16 Apr 2026 16:52:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html si-local-file:///var/storage/secattach/20260416/26325752.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html Thu, 16 Apr 2026 16:52:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Globe+Newswire/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Globe+Newswire/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Globe+Newswire/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Globe+Newswire/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Globe+Newswire/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Globe+Newswire/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Globe+Newswire/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Globe+Newswire/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Globe+Newswire/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Globe+Newswire/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Reports+Full+Year+2025+Financial+Results+and+Business+Update/26225567.html <p align="right">Châtillon, France, March 26, 2026</p> <p align="justify"><b>DBV Technologies Reports Full Year 2025 Financial Results and Business Update</b></p> <ul type="disc"><li style="text-align:justify;">Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)</li><li style="text-align:justify;">Bolstered executive leadership team in preparation for BLA submission and potential approval</li><li style="text-align:justify;">Reported cash and cash equivalents of $194 million as of December 31, 2025, plus additional gross proceeds of $94 million received on January 16, 2026 —providing funding into the second quarter of 2027<br/><br/></li></ul> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Reports+Full+Year+2025+Financial+Results+and+Business+Update/26225567.html Thu, 26 Mar 2026 17:06:00 -0400 A.26800952 A.50201579 DBV DBVT O.00711722 O.12524441 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Reports+Full+Year+2025+Financial+Results+and+Business+Update/26225567.html <p align="right">Châtillon, France, March 26, 2026</p> <p align="justify"><b>DBV Technologies Reports Full Year 2025 Financial Results and Business Update</b></p> <ul type="disc"><li style="text-align:justify;">Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)</li><li style="text-align:justify;">Bolstered executive leadership team in preparation for BLA submission and potential approval</li><li style="text-align:justify;">Reported cash and cash equivalents of $194 million as of December 31, 2025, plus additional gross proceeds of $94 million received on January 16, 2026 —providing funding into the second quarter of 2027<br/><br/></li></ul> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Reports+Full+Year+2025+Financial+Results+and+Business+Update/26225567.html Thu, 26 Mar 2026 17:06:00 -0400 A.26800952 A.50201579 DBV DBVT O.00711722 O.12524441 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Reports+Full+Year+2025+Financial+Results+and+Business+Update/26225567.html <p align="right">Châtillon, France, March 26, 2026</p> <p align="justify"><b>DBV Technologies Reports Full Year 2025 Financial Results and Business Update</b></p> <ul type="disc"><li style="text-align:justify;">Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)</li><li style="text-align:justify;">Bolstered executive leadership team in preparation for BLA submission and potential approval</li><li style="text-align:justify;">Reported cash and cash equivalents of $194 million as of December 31, 2025, plus additional gross proceeds of $94 million received on January 16, 2026 —providing funding into the second quarter of 2027<br/><br/></li></ul> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Reports+Full+Year+2025+Financial+Results+and+Business+Update/26225567.html Thu, 26 Mar 2026 17:06:00 -0400 A.26800952 A.50201579 DBV DBVT O.00711722 O.12524441 O.26593910